Member Info for LemonsToRiches

£2583@10% ALL get $2324.70. Back on track after $83 gap. 🤷‍♂️

Into the final furlong, or rather the final few weeks of Q4. Bring on the RTO.

03 October 2025

Lansdowne Oil & Gas plc

("Lansdowne" or the "Company")

Update on Reverse Takeover ("RTO")

Lansdowne Oil & Gas plc pleased to provide an update on the progress of the planned Reverse Takeover.

As previously announced, trading in the Company's shares on AIM has been suspended pending the completion of the RTO, which requires the publication of an admission document, the approval of such a transaction at the Annual General Meeting of the Company and the readmission of the Company's shares to trading on AIM. The Company is pleased to advise that all the RTO workstreams are well advanced with completion of the RTO targeted for Q4 2025.

Remember the presentation in October where we were told "One minute past midnight on the 31 October it'll be trick or treat time"?

What that was telling us is that if Ireland didn't give PRD a suitable reply to its demands of a decision, with some options provided by PRD, if Ireland ignored that request then litigation would be initiated at 00:00:01 on 1 November.

As there has been no news to the contrary, PRD are already well into the litigation process.

Once PRD have had independent financial loss adjusters from the O&G sector calculate the size of the claim, then the claim can be submitted to the ICSID. At that point we should get an RNS detailing what Ireland are being charged with and the size of the claim.

Incidentally, the ICSID is a World Bank organisation, they are the pinnacle of international commercial courts.

It's been almost 5 weeks since litigation was initiated, so I feel we are getting close to an RNS with the amount being claimed, which undoubtedly will be far more than the current company valuation of £21.96m.

Class action lawsuit doesn't exist in the UK.

Also, each affected company has different grounds for litigation, it's not a one size fits all situation, so a class action wouldn't be suitable. Any single claim from multiple companies would bring huge complexity in the claims and who would decide how much each party gets of any award?

LOGP had their progress blocked by a decision that was clearly biased by the minister.

PRD have not had a blocking decision, the issue is that they've had no decision, and it's that lack of a decision that's prevented any progress.

The standard way to fix things is arbitration, but Ireland doesn't want to fix things it wants companies to go bust so that the issues evaporate, so Ireland would only use arbitration as a delaying tactic.

Both companies litigation is likely to be through the ICSID for breach of the Treaty between the UK and Ireland that protects UK companies investing in Ireland and vice versa.

LG could certainly buy us out to erase the ECT claim. The NPV plus losses is around the market cap of £123m so why wouldn't he pay that if it gives him free reign to push for Barryroe development which is worth billions, whilst using his Jersey company to pursue an ECT claim as a way of forcing the Government to let him develop Barryroe or pay him off in multiples of the £123m it costs to take us out of the picture.

He called in the examiner on Barryroe and then picked the company up dirt cheap in his 'rescue plan", wiping out loads of other investors. He could easily do the same to us, based on the way he does his business.

"Mr Goodman’s Vevan Unlimited vehicle, which last July petitioned for the appointment of an examiner to Barryroe" and then "Larry Goodman’s €6m Barryroe rescue plan approved by High Court. Most shareholders to be wiped out in scheme that will mean explorer turns to renewable-energy opportunities."

The desperation of these VAL bashers should be telling everyone how much they want to load up with this stock and are posting all this bashing purely to try and keep the price down while they accumulate.

Nobody wastes any time on stocks they have no interest in owning, they spend their time on the stocks they hold or want to accumulate.

Don't be fooled by the con artists.

Ah I see, it's another VAL bashing moron to filter.

Today's deal makes FOUR in the two months since the results Webinar.

Mark is on a mission!

Who's PM2022?

Quite often drug discoveries are made in projects like Stingray and, the continuation of it into the new agreement says all those involved believe there is some value in it, otherwise they would have ended it here and now. They are the experts, they know what they are looking at, the bashers on here don't know a thing that the experts can see, so it's obvious who to believe and who to ignore.

Paternostpauper, LOL! 🤣🤣

They know everyone has them filtered, they are so deluded they think if they keep posting they affect the share price or wind-up the longs, one day they'll realise they wasted their lives LOL! 🤣🤣

Those green boxes are so eco-friendly just like the one's in my garden, they keep growing!

"This message has been filtered, please adjust your filters to view"

This is very different to developing a cancer test, this actually tests the cancer against many different treatments to pick the best treatment option before treatment starts. That's very novel, it's innovative and pioneering (as stated in the press articles), it's not something other companies are doing, I've searched and found some AI systems for cancer analysis, mainly still in university studies, but nothing that predicts the best treatment let alone per patient.

"PredictRx is a personalised cancer screening service in which a patient’s tumour sample is processed into Patient Derived Cells (PDCs) and screened against a panel of drug combinations to support the identification of optimal chemotherapy treatment strategies."

"This can deliver significant benefit by identifying the most effective treatment options leading to a truly personalised approach to therapy which ultimately should deliver improved outcomes for patients."

People shouldn't bash stocks doing things like this, they never know if they might need what this company is developing one day.

"We're delighted to expand our successful partnership with Inaphaea by bringing the PredictRx platform to market globally."

Servier, global partner of Dominion. If they take PredictRx global on behalf of Dominion then that would be a big leap. I'm not sure how else Dominion would take it global as per the above statement, any other ideas?

https://servier.com/en/servier-group/servier-throughout-the-world/

Trying to belittle other people, trying to make out you are the all knowing Messiah with the working crystal ball, trying to talk down what is excellent news simply because you have no vision other than short term gains, that says only one thing to me, best ignored, so on the filter you go.

I like that we've had deals signed with Ambrose, Voxcell and now Dominion, that's three deals in less than two months since the results Webinar, where Mark said he was targeting the warrants price and spoke comparatively about £350m companies.

Mark delivers and keeps on delivering. It'll take off one day in the near future IMO.

Ignore the history lessons, the future is very bright here.

Badsterman,

"initial revenues"

I'm looking further than "initial revenues".

This should really take off past "initial revenues" and become huge. It's a game changer.

This is amazing news! PredictRx is going GLOBAL! It's such a huge innovation for Cancer treatment that every Oncology department should demand it.

"Inaphaea's focus is translational drug development services and monetising of its biobank through its PDC models and through this license to Dominion which will develop and commercialise the PredictRx clinical service globally."

Anthony Holmes, CEO of Dominion commented "We're delighted to expand our successful partnership with Inaphaea by bringing the PredictRx platform to market globally. This innovative personalised cancer screening service represents a significant advancement in precision oncology - using a patient's own cancer cells to identify the most effective treatment options before therapy begins. By leveraging our established network of oncologists and patient-derived cell expertise, we can now offer clinicians and patients a powerful tool to optimise treatment decisions from day one. This licensing agreement demonstrates our commitment to translating cutting-edge science into real-world clinical benefits that can improve patient outcomes and potentially reduce the trial-and-error approach that too often characterises cancer treatment today."

Https://www.researchgate.net/profile/Charles-Chen-11

Https://www.imperial.ac.uk/news/262133/retrosynthesis-competition-chemistry-students-take-prize/